Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CPI-006 · 2 trials · 14 indications
Incidence of adverse events (including serious adverse events and dose limiting toxicities).
Measure changes in serum or plasma immunoglobulin anti-SARS CoV-2 levels.
| Arm | Type | Description |
|---|---|---|
| CPI-006 Dose Escalation | EXPERIMENTAL | CPI-006 + Standard of Care |
| Control Arm | OTHER | Standard of Care Only |
| Cohort 1a | EXPERIMENTAL | CPI-006 |
| Cohort1b | EXPERIMENTAL | CPI-006 + ciforadenant |
| Cohort 1c | EXPERIMENTAL | CPI-006 + pembrolizumab |
| Cohort 2a | EXPERIMENTAL | CPI-006 |
| Cohort 2b | EXPERIMENTAL | CPI-006 + ciforadenant |
| Cohort 2c | EXPERIMENTAL | CPI-006 + pembrolizumab |
| Name | Type | Description |
|---|---|---|
| CPI-006 | DRUG | Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care. |
| Standard of Care | OTHER | Participants will receive standard of care treatment only. |
| CPI-006 + ciforadenant | DRUG | Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression. |
| CPI-006 + pembrolizumab | DRUG | Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression. |
Inclusion Criteria: * Nasal swab test positive by reverse transcriptase PCR for SARS CoV-2 within past 7 days, and onset of COVID-19 symptoms no more than 10 days prior to the positive test * Hospitalized and have stable mild to moderate symptoms of COVID-19 * Blood oxygen saturation of a minimum o...
CPI-006 is an investigational small molecule being studied for COVID-19 and Non-Small Cell Lung Cancer. It is developed by Corvus Pharmaceuticals, Inc. (CRVS) and is currently in Phase 1 clinical development. CPI-006 has been evaluated in clinical trials for these indications, though it remains investigational and is not yet approved.
CPI-006 is being developed by Corvus Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker CRVS. The company is conducting clinical trials to evaluate CPI-006 as a potential treatment for COVID-19 and Non-Small Cell Lung Cancer.
CPI-006 is in Phase 1 clinical development. It has completed two Phase 1 trials, one in advanced cancers including Non-Small Cell Lung Cancer and another in hospitalized COVID-19 patients. CPI-006 is investigational and has not been approved by regulatory authorities.
CPI-006 has been studied in two completed Phase 1 clinical trials. NCT03454451 evaluated CPI-006 alone and in combination with ciforadenant and pembrolizumab in patients with advanced cancers, including Non-Small Cell Lung Cancer. NCT04464395 studied CPI-006 as immunotherapy for hospitalized COVID-19 patients.
No, CPI-006 is a distinct investigational small molecule. In clinical trial NCT03454451, CPI-006 was studied alone and in combination with ciforadenant and with pembrolizumab, which are separate drugs. CPI-006 is not the same as either of these agents.